A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910